Company in the news
A wonderful commentary by our Board Member, Dr. Eckhard von Keutz, published in Regulatory Toxicology and Pharmacology in June 2025 highlights a path forward for new approach methodologies (NAMs) and their utility in predicting DILI. The time to act is now!
Lena Biosciences is proud to participate in the 3Rs Collaborative drug-induced liver injury platform validation. In partnership with the 3Rs Collaborative, the Critical Path Institute, the FDA - CDER, the National Institutes of Health - NICEATM, technology providers and end users.
Press release
Lena Biosciences appoints Dr. Eckhard von Keutz to its Business Advisory Board and Science Advisory Board
Announcements and awards
August, 2024
Lena Biosciences is awarded $1.96 M Phase II SBIR
to develop a "virtual human population" screen for predictive toxicology
which incorporates human genetic variability to isolate:
Lena Biosciences is awarded $1.96 M Phase II SBIR
to develop a "virtual human population" screen for predictive toxicology
which incorporates human genetic variability to isolate:
- Sensitive individuals; early responders to toxicants
- Susceptible individuals who respond adversely to lower doses of toxicants than an "average" human, and
- Vulnerable individuals who respond to toxicants through different dose-dependent mechanisms
Landmark study with PerfusionPal featured in PLoS One:
Drug testing in fully humanized, 3D, perfused breast cancer model |
Lena Biosciences receives over $1.8 M Phase II SBIR grant award to apply its screening platform to toxicity testing of chemicals implicated in neurodegenerative diseases
|
2022 Finalist
Mass Challenge US Early Stage Accelerator |
Lena Biosciences receives $300 K Phase I SBIR grant award to apply its screening platform to drug-induced liver injury
|
Finalist RESI Longevity Pitch Challenge
Therapeutics and Diagnostics, Sept. 2021 |
Lena Biosciences publishes Phase I drug metabolism results with PerfusionPal
|
Interdigitated electrodes on SeedEZ scaffolds monitor cardiomyocyte growth
|
Lena Biosciences receives $252 K Phase I SBIR grant award to apply its screening platform to toxicity testing of agrochemicals
|
Lena Biosciences and SpeciCare, a tumor tissue bank, announce collaboration
|